Clinical Trials List
2025-07-01 - 2028-05-31
Phase III
Recruiting5
ICD-10I70.0
Atherosclerosis of aorta
ICD-9440.0
Atherosclerosis of aorta
-
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/13
Investigators and Locations
Co-Principal Investigator
- Po-Sheng Chen Division of General Internal Medicine
- 葉建寬 Division of General Internal Medicine
- 陳則瑋 Division of General Internal Medicine
- 黃鼎鈞 Division of General Internal Medicine
- 張獻元 Division of General Internal Medicine
- 黃睦翔 Division of General Internal Medicine
- 鄭朝允 Division of General Internal Medicine
- 李文煌 Division of General Internal Medicine
- Po Wei Chen Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chern-En Chiang Division of Cardiovascular Diseases
- 李慶威 Division of Cardiovascular Diseases
- 蔡依霖 Division of Cardiovascular Diseases
- Shih-Hsien Sung Division of Cardiovascular Diseases
- 黃偉銘 Division of Cardiovascular Diseases
- 吳承學 Division of Cardiovascular Diseases
- 曾致學 Division of Cardiovascular Diseases
- Wen-Chung Yu Division of Cardiovascular Diseases
- 張俊欽 Division of Cardiovascular Diseases
- Tse-Min Lu Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 吳韋璁 Division of Cardiovascular Diseases
- Chun-Yuan Chu Division of Cardiovascular Diseases
- Ye-Hsu Lu Division of Cardiovascular Diseases
- 黃天祈 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 洪啟盛 Division of General Internal Medicine
- HUNG-JU LIN Division of General Internal Medicine
- 賀立婷 Division of General Internal Medicine
- 林柏志 Division of General Internal Medicine
- 陳盈憲 Division of General Internal Medicine
- JEN-KUANG LEE Division of General Internal Medicine
- Hsien Li Kao Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
19 participants
-
Global
340 participants
